JPMorgan Chase & Co. Has $4.12 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

JPMorgan Chase & Co. lowered its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 14.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 205,955 shares of the biotechnology company's stock after selling 33,633 shares during the period. JPMorgan Chase & Co. owned 0.09% of ADMA Biologics worth $4,117,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. USA Financial Formulas increased its stake in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after buying an additional 539 shares during the period. Vontobel Holding Ltd. boosted its holdings in ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after acquiring an additional 888 shares during the last quarter. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the third quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock worth $163,000 after purchasing an additional 1,509 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new position in ADMA Biologics during the 3rd quarter valued at about $31,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 3.7 %

ADMA Biologics stock opened at $16.02 on Friday. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of 57.21 and a beta of 0.76. The company's 50 day simple moving average is $19.04 and its 200 day simple moving average is $17.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a fifty-two week low of $4.86 and a fifty-two week high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same period last year, the firm posted $0.01 earnings per share. As a group, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ADMA shares. Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.